Drug intelligence / Profile preview

Re-esterified triglyceride omega-3 fatty acids

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Re-esterified triglycerides (rTGs) are a highly bioavailable form of omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). They are derived from fish oil and are utilized as dietary supplements. These fatty acids are known to positively influence lipid profiles, vascular tone, and blood coagulation, and also possess anti-inflammatory properties. They play a central role in the functioning of the brain and central nervous system, contributing to overall health and disease prevention.

Other names: Omega-3 fatty acids (re-esterified triglyceride form)

Beyond the preview

Go deeper on Re-esterified triglyceride omega-3 fatty acids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Re-esterified triglyceride omega-3 fatty acids.

Explore the full profile